
Top chief, Torsten Freltoft, hopes his company ChemoMetec will truly find its footing on the lucrative US market, but it neither can nor will happen overnight. The increased focus on the US market already started to pay off in the past fiscal year, and that development should continue in coming years.
In the fiscal year 2012/2013, the company presented turnover of DKK 41.4m (USD 7.5m), expected to grow slightly to DKK 43-45m (USD 7.8-8.2m) in the coming financial year.
Allerede abonnent? Log ind.
Læs hele artiklen
Få adgang i 14 dage for 0 kr.
Det kræver intet kreditkort, og du vil ikke overgå til et betalt abonnement efterfølgende.
- Adgang til alle låste artikler
- Modtag vores daglige nyhedsbreve
- Fuld adgang til vores app